| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,572 | 1,674 | 16.11. | |
| 1,612 | 1,658 | 16.11. |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.11. | ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital | 273 | Business Wire | Article L233-8-II of the French Commercial Code
Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)
Regulatory News:
ABIONYX Pharma (Paris:ABNX):
Market:... ► Artikel lesen | |
| 04.11. | ABIONYX Pharma Signs a Strategic Partnership with Lille University Hospital-Burn Treatment Center and Intensive Care Unit-to Explore the Potential of CER-001 in Severe Burn Patients at High Risk for Sepsis | 405 | Business Wire | Patients with severe burns and those in intensive care and resuscitation: populations at very high risk of sepsis and multi-organ failure, at the heart of the continuum between severe acute inflammation... ► Artikel lesen | |
| ABIONYX PHARMA Aktie jetzt für 0€ handeln | |||||
| 27.10. | ABIONYX Pharma Finalizes the Structuring of Its CER-001 Bioproduction Chain Through a Strategic Partnership with AXPLORA, Marking a Major Milestone Toward Its Potential Commercialization | 485 | Business Wire | An end-to-end manufacturing process for the purification of recombinant human apoA-I has now been finalized with AXPLORA A decisive step toward potential first-in-class commercialization... ► Artikel lesen | |
| 07.10. | Abionyx, Olon Partner to Develop and Commercialize Sepsis Treatment | 4 | Contract Pharma | ||
| 07.10. | ABIONYX Pharma and OLON Enter Into Strategic Manufacturing Partnership to Prepare CER-001 Biologic for Regulatory Approval and Commercial Supply | 420 | Business Wire | CER-001: a distinctive manufacturing challenge to produce a full-length recombinant human apoA-I, a 243-amino-acid protein to form a biomimetic HDL particle A strategic partnership including... ► Artikel lesen | |
| 02.10. | ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital | 596 | Business Wire | Article L233-8-II of the French Commercial Code Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)
Regulatory News:
ABIONYX Pharma (Paris:ABNX):
Market:... ► Artikel lesen | |
| 02.10. | ABIONYX Pharma Announces the Settlement of an Anticipated Amortization Payment in Accordance With the Terms of Its Bonds Financing Agreement | 614 | Business Wire | Anticipated amortization payment of EUR 1.75 million in principal under the Bonds financing EUR 0.52 million settled through the issuance of 331,299 new ordinary shares to Fenja Capital... ► Artikel lesen | |
| 23.09. | ABIONYX Pharma: Half Year Results 2026 | 545 | Business Wire | Cash balance of €26.9 million as of June 30, 2026, before tax credits and grants under the France 2030 plan
Focus on strategy execution and rigorous program implementation in LCAT... ► Artikel lesen | |
| 10.09. | ABIONYX Pharma Reaches Another Key Milestone in the Industrialization of CER-001 by Entering into a Strategic Partnership with TEXCELL (ABL Diagnostics) for the Viral Safety and Clearance of Biologics | 637 | Business Wire | Preparation of validation batches for the CER-001 bioproduction process based on viral safety studies A key step in the industrial and regulatory dossier toward a future market launch for... ► Artikel lesen | |
| 10.09. | ABL Diagnostics - TEXCELL Strengthens Its Position as an International Reference in Safety and Viral Clearance With a New Strategic Partnership With ABIONYX Pharma | 721 | Business Wire | • Selection of ABL Diagnostics' TEXCELL division for CER-001 viral safety and clearance studies • Support for a key stage of ABIONYX Pharma's industrial and regulatory program • Confirmation... ► Artikel lesen | |
| 07.09. | ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital | 558 | Business Wire | Article L233-8-II of the French Commercial Code Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)
Regulatory News:
ABIONYX Pharma (Paris:ABNX):
Market:... ► Artikel lesen | |
| 27.08. | ABIONYX Pharma Provides an Update on Its Activity and Cash Position for the First Half of 2026 | 655 | Business Wire | Consolidated revenue of €1.9 million as of the end of June 2026 Cash balance of €26.9 million as of June 30, 2026 prior to receiving Research Tax Credits and grants under the France 2030... ► Artikel lesen | |
| 04.08. | ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital | 470 | Business Wire | Article L233-8-II of the French Commercial Code
Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)
Regulatory News:
ABIONYX Pharma (Paris:ABNX):
Market:... ► Artikel lesen | |
| 06.07. | ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital | 526 | Business Wire | Article L233-8-II of the French Commercial Code
Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)
Regulatory News:
ABIONYX Pharma (Paris:ABNX):
Market:... ► Artikel lesen | |
| 06.07. | ABIONYX Pharma: Half-Year Review of the Liquidity Agreement Entered into with TP ICAP (Europe) SA | 992 | Business Wire | Regulatory News:
Under the liquidity agreement covering the shares of ABIONYX Pharma (FR0012616852 ABNX FP) entrusted to TP ICAP (Europe), the following assets were held in the liquidity account... ► Artikel lesen | |
| 30.06. | ABIONYX Pharma is Scaling up Its Operations After Securing the Resources Needed to Achieve Its Goals and Is Embarking on a New Cycle of Value Creation in the Treatment of Severe Inflammation and Sepsis | 665 | Business Wire | All resolutions submitted for a vote at today's Combined General Meeting were approved Launch of the largest pivotal clinical trial for CER-001 in sepsis, the 3rd cause of death worldwide... ► Artikel lesen | |
| 18.06. | ABIONYX Pharma Announces the Success of its Financing for a Total Maximum Amount of EUR 33 M | 1.036 | Business Wire | Capital increase fully subscribed for a total amount of EUR 18.7 M through the issuance of 7,056,416 New Shares at a subscription price of EUR 2.65 per share Drawdown of the First Tranche... ► Artikel lesen | |
| 09.06. | ABIONYX Pharma: Combined Annual Shareholders' Meeting on June 30, 2026: Availability of preparatory documents and procedures for participation and voting | 492 | Business Wire | Regulatory News:
ABIONYX Pharma, (FR0012616852 ABNX PEA PME eligible), a next-generation biopharmaceutical company developing innovative therapies for sepsis and critical care based on a proprietary... ► Artikel lesen | |
| 02.06. | ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital | 480 | Business Wire | Article L233-8-II of the French Commercial Code
Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)
Regulatory News:
ABIONYX Pharma (Paris:ABNX):
Market:... ► Artikel lesen | |
| 29.05. | XFRA CAPITAL ADJUSTMENT INFORMATION - 29.05.2026 | 598 | Xetra Newsboard | Das Instrument TAH JP3634600005 TOYOTA INDS EQUITY wird cum Kapitalmassnahme gehandelt am 29.05.2026 und ex Kapitalmassnahme am 01.06.2026 The instrument TAH JP3634600005 TOYOTA INDS EQUITY is traded... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 78,30 | +0,84 % | BioNTech-Aktie: Totes Kapital? | Die Aktie von BioNTech bleibt trotz des rückläufigen Impfstoffgeschäfts ein spannender Titel am Aktienmarkt. Anleger richten ihren Blick zunehmend auf die milliardenschwere Forschungspipeline im Bereich... ► Artikel lesen | |
| EVOTEC | 2,966 | -5,06 % | Evotec-Aktie: Gewinn- und Umsatzrekord? | Die Aktie des Hamburger Wirkstoffforschers Evotec bleibt ein spannender, aber risikoreicher Titel am deutschen Aktienmarkt. Nach schwierigen Monaten sorgen erste operative Fortschritte, neue Partnerschaften... ► Artikel lesen | |
| BB BIOTECH | 58,00 | -1,36 % | Christian Koch, Leiter BB Biotech Team bei Bellevue Asset Management, im Interview | von Robert Jakob Moneycab.com: Herr Koch, acht bestehende Beteiligungen verkauft, zwölf neue Positionen aufgebaut, das sieht nach einer grösseren Rochade aus? Die Veränderungen spiegeln unser aktives... ► Artikel lesen | |
| MEDIGENE | 0,003 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 30.06.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 30.06.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 30.06.2026ISIN NameBE0003593044 COFINIMMOCA8765111064 TASEKO... ► Artikel lesen | |
| QIAGEN | 45,310 | +0,13 % | QIAGEN N.V.: QIAGEN-Aktionäre stimmen der Berufung von Jonathan M. Pratt in die Geschäftsführung mit überwältigender Mehrheit zu | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute bekannt gegeben, dass die Aktionärinnen und Aktionäre auf einer Außerordentlichen Hauptversammlung der Berufung von Jonathan M. Pratt... ► Artikel lesen | |
| MODERNA | 196,16 | -3,18 % | Moderna nach 300 % Rallye: Droht jetzt eine größere Korrektur? | Seit August verzeichnete Moderna einen deutlichen Kursanstieg, auf den zuletzt eine Zwischenkorrektur folgte. Die bisher intakte Folge höherer Hochs und Tiefs sowie die zuletzt verteidigte 50-Tage-Linie... ► Artikel lesen | |
| VALNEVA | 2,600 | +0,89 % | Valneva: Neue Langzeitdaten für Chikungunya-Impfstoff | Valneva hat neue Langzeitdaten zu seinem Chikungunya-Impfstoff IXCHIQ vorgelegt. Fünf Jahre nach einer einmaligen Impfung wiesen noch 94 Prozent der 221 auswertbaren Studienteilnehmer neutralisierende... ► Artikel lesen | |
| AMGEN | 426,55 | +0,96 % | Amgen Announces Positive Phase 3 Results For Dazodalibep In Sjögren's Disease | Only Global Phase 3 Trial to Show Clinically Meaningful Improvements in Systemic Disease Activity and Patient-Reported Symptoms of Sjögren's Disease THOUSAND OAKS, Calif., Nov. 11, 2026 /PRNewswire/... ► Artikel lesen | |
| EPIGENOMICS | 0,870 | 0,00 % | PTA-PVR: Epigenomics AG: Veröffentlichung nach § 40 Abs. 1 WpHG | DJ PTA-PVR: Epigenomics AG: Veröffentlichung nach § 40 Abs. 1 WpHG
Veröffentlichung gem. -- 40 Abs. 1 WpHG
Epigenomics AG: Veröffentlichung nach -- 40 Abs. 1 WpHG
Heidelberg (pta000/26.10.2026/15:00... ► Artikel lesen | |
| NOVAVAX | 7,430 | -4,01 % | Novavax: Starke Zahlen, schwache Aktie - was zählt jetzt? | ||
| STRYKER | 283,90 | +1,07 % | Stryker: Millionenverkauf - was Anleger jetzt prüfen sollten | ||
| BIOGEN | 230,35 | +0,13 % | TRIMTECH Therapeutics Enters Strategic Research Collaboration With Biogen to Advance Small Molecule Degraders for Neurodegenerative Disease | Collaboration with Biogen will leverage TRIMTECH's proprietary TRIM21-based targeted protein degradation technology to develop novel protein degrading therapeutics for neurodegenerative diseases.... ► Artikel lesen | |
| BIOFRONTERA | 2,770 | 0,00 % | Biofrontera: Was hinter dem Liquiditätsdruck steckt | ||
| HEIDELBERG PHARMA | 2,140 | +3,38 % | Formycon, Heidelberg Pharma und Medios: Biotech-Nebenwerte zwischen Analystenrückenwind und stillen Kursen | ||
| CRISPR THERAPEUTICS | 38,200 | -0,27 % | CRISPR Therapeutics Highlights Substantial Lipid Reductions with Investigational Gene Editing Therapy |